Cargando…

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

BACKGROUND: A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines. MATERIALS AND METHODS: The combination of the BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niehr, Franziska, von Euw, Erika, Attar, Narsis, Guo, Deliang, Matsunaga, Doug, Sazegar, Hooman, Ng, Charles, Glaspy, John A, Recio, Juan A, Lo, Roger S, Mischel, Paul S, Comin-Anduix, Begonya, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152784/ https://www.ncbi.nlm.nih.gov/pubmed/21609436 http://dx.doi.org/10.1186/1479-5876-9-76

Ejemplares similares

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy
por: Bustos, Silvina Odete, et al.
Publicado: (2018)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
por: Choi, Jaehyuk, et al.
Publicado: (2014)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
por: Garbarino, Ombretta, et al.
Publicado: (2023)

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells
por: George, Andrea L., et al.
Publicado: (2015)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
por: Basile, Kevin J., et al.
Publicado: (2011)

Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
por: Erdmann, Sarah, et al.
Publicado: (2019)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells
por: Li, Yanling, et al.
Publicado: (2015)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Texture-Induced Corrosion Resistance of Dissimilar AA7204/AA6082 Friction Stir Welded Joints
por: Guan, Liqun, et al.
Publicado: (2023)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-κB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro
por: Liu, Jia-Fang, et al.
Publicado: (2018)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Beyond the immediate tumor microenvironment: distinct T cell phenotype and function of tumor-adjacent healthy breast tissue associated with regional metastasis in breast cancer
por: Guo, Yi, et al.
Publicado: (2014)

Plx1 is required for chromosomal DNA replication under stressful conditions
por: Trenz, Kristina, et al.
Publicado: (2008)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Putting PLX5622 into perspective: microglia in central nervous system viral infection
por: Spiteri, Alanna G., et al.
Publicado: (2022)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis
por: Mein, Nils, et al.
Publicado: (2023)

4032 An exploration of the perceptions of young women with breast cancer with varying health literacy levels about the usefulness of cancer educational materials
por: Parker, Pearman, et al.
Publicado: (2020)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Complete remission of critical neurohistiocytosis by vemurafenib
por: Euskirchen, Philipp, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jglq6laki5rkrgic97rquncvi9